Mon panier

PE-Labeled Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (Site-specific conjugation)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-HP2E4-25tests
$1470.00
CD0-HP2E4-200tests
$7320.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonym

    MS4A1, CD20, MS4A-1

  • Source

    PE-Labeled Human CD20 Full Length Protein, His Tag (CD0-HP2E4) is produced via site-specific conjugation of PE to Human CD20 Full Length Protein, His Tag under optimal conditions with a proprietary technology. Human CD20 Full Length Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

    Request for sequence

  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 36.9 kDa.

    Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by an amphipathic scaffold coat that confers enhanced stability and a narrow particle size distribution.

    The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein upon removal of the detergent.

  • Conjugate

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process
  • *The isotype control of empty/mock nanodisc (Cat. No. APO-HP1E3) is sold separately and not included in protein, you can follow this link for product information.

Les clients ont également consulté

Affichage des données

  • Bioactivity-FACS

     CD20 FACS

    5e5 of Anti-CD20 CAR-293 cells were stained with 100 μL of 1:20 dilution (5 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HP2E4) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).​

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD20

  • Catégorie:

  • Nombre de médicaments répertoriés:

    35 Détails

  • Nombre de médicaments cliniques:

    132 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte